Status:
NOT_YET_RECRUITING
Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)
Lead Sponsor:
King Faisal Specialist Hospital & Research Center
Conditions:
Small-for-Size Syndrome
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
The goal of this clinical trial is to compare two treatments for regulating blood flow in small liver grafts during living donor liver transplantation (LDLT). The main questions it aims to answer are:...
Detailed Description
This randomized controlled trial (SCALOP-RCT) investigates two strategies for managing portal hyperperfusion in adults receiving small living donor liver transplants (graft-to-recipient weight ratio \...
Eligibility Criteria
Inclusion
- Age ≥ 18 and \<70 years
- Male and female genders
- Undergoing Living Donor Liver Transplant (LDLT)
- All indications
- Receiving a small-for-size graft requiring portal flow modulation
- Informed consent provided.
Exclusion
- Deceased Donor Liver Transplantation (DDLT)
- Dual LDLT or dual LDLT/DDLT
- Pregnancy
- Known allergy to Octreotide / Somatostatin analogue
Key Trial Info
Start Date :
June 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2030
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06974344
Start Date
June 1 2025
End Date
September 1 2030
Last Update
May 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center
Riyadh, Saudi Arabia, 12713